Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$1.0 million.

  • Beam Therapeutics' Gains from Investment Securities fell 109.96% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 4.75%. This contributed to the annual value of $9.6 million for FY2024, which is 16.06% up from last year.
  • Per Beam Therapeutics' latest filing, its Gains from Investment Securities stood at -$1.0 million for Q3 2025, which was down 3,671.43% from $28,000 recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Gains from Investment Securities peaked at $60.9 million during Q4 2021, and registered a low of -$12.5 million during Q4 2022.
  • Over the past 3 years, Beam Therapeutics' median Gains from Investment Securities value was $617,000 (recorded in 2023), while the average stood at $5.4 million.
  • Per our database at Business Quant, Beam Therapeutics' Gains from Investment Securities plummeted by 388.33% in 2024 and then spiked by 6,468.40% in 2025.
  • Beam Therapeutics' Gains from Investment Securities (Quarterly) stood at $60.9 million in 2021, then plummeted by 120.48% to -$12.5 million in 2022, then soared by 247.31% to $18.4 million in 2023, then slumped by 32.98% to $12.3 million in 2024, then crashed by 109.96% to -$1.0 million in 2025.
  • Its Gains from Investment Securities was -$1.0 million in Q3 2025, compared to $28,000 in Q2 2025 and $11.6 million in Q1 2025.